Julia L Marcus1, Kenneth Levine1, Chris Grasso1, Douglas S Krakower1, Victoria Powell1, Kyle T Bernstein1, Stephen Boswell1, Kenneth H Mayer1. 1. Julia L. Marcus is with the Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA. Kenneth Levine, Chris Grasso, Douglas S. Krakower, Victoria Powell, Stephen Boswell, and Kenneth H. Mayer are with the Fenway Institute, Fenway Health, Boston, MA. Kyle T. Bernstein is with the Centers for Disease Control and Prevention, Atlanta, GA.
Abstract
OBJECTIVES: To determine whether HIV preexposure prophylaxis (PrEP) use is associated with use of non-HIV-related health care. METHODS: We conducted a cross-sectional study of potential PrEP candidates at a Boston, Massachusetts, community health clinic during 2012 to 2016, comparing the proportion of PrEP users and non-PrEP users receiving primary care. RESULTS: Of 5857 PrEP candidates, 2047 (35%) were prescribed PrEP. After adjustment for demographics and number of visits, more PrEP users received influenza vaccination (prevalence ratio [PR] = 1.28; 95% confidence interval [CI] = 1.20, 1.37), tobacco screening (PR = 1.06; 95% CI = 1.02, 1.09), and depression screening (PR = 1.07; 95% CI = 1.04, 1.11) compared with non-PrEP users. After additional adjustment for diabetes, hypertension, and overweight or obesity, more PrEP users received glucose testing (PR = 1.64; 95% CI = 1.56, 1.72) but fewer received hemoglobin A1c testing (PR = 0.81; 95% CI = 0.71, 0.93) compared with non-PrEP users. CONCLUSIONS: PrEP use was associated with receipt of influenza vaccination, tobacco and depression screening, and glucose but not hemoglobin A1c testing. Among PrEP users receiving routine care, the benefits of PrEP may extend to behavioral health, mental health, and prevention and treatment of other infectious and chronic diseases.
OBJECTIVES: To determine whether HIV preexposure prophylaxis (PrEP) use is associated with use of non-HIV-related health care. METHODS: We conducted a cross-sectional study of potential PrEP candidates at a Boston, Massachusetts, community health clinic during 2012 to 2016, comparing the proportion of PrEP users and non-PrEP users receiving primary care. RESULTS: Of 5857 PrEP candidates, 2047 (35%) were prescribed PrEP. After adjustment for demographics and number of visits, more PrEP users received influenza vaccination (prevalence ratio [PR] = 1.28; 95% confidence interval [CI] = 1.20, 1.37), tobacco screening (PR = 1.06; 95% CI = 1.02, 1.09), and depression screening (PR = 1.07; 95% CI = 1.04, 1.11) compared with non-PrEP users. After additional adjustment for diabetes, hypertension, and overweight or obesity, more PrEP users received glucose testing (PR = 1.64; 95% CI = 1.56, 1.72) but fewer received hemoglobin A1c testing (PR = 0.81; 95% CI = 0.71, 0.93) compared with non-PrEP users. CONCLUSIONS: PrEP use was associated with receipt of influenza vaccination, tobacco and depression screening, and glucose but not hemoglobin A1c testing. Among PrEP users receiving routine care, the benefits of PrEP may extend to behavioral health, mental health, and prevention and treatment of other infectious and chronic diseases.
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Samuel M Jenness; Kevin M Weiss; Steven M Goodreau; Thomas Gift; Harrell Chesson; Karen W Hoover; Dawn K Smith; Albert Y Liu; Patrick S Sullivan; Eli S Rosenberg Journal: Clin Infect Dis Date: 2017-09-01 Impact factor: 9.079
Authors: Rennatus Mdodo; Emma L Frazier; Shanta R Dube; Christine L Mattson; Madeline Y Sutton; John T Brooks; Jacek Skarbinski Journal: Ann Intern Med Date: 2015-03-03 Impact factor: 25.391
Authors: Mark L Hatzenbuehler; Katie A McLaughlin; Katherine M Keyes; Deborah S Hasin Journal: Am J Public Health Date: 2010-01-14 Impact factor: 9.308
Authors: Jonathan E Volk; Julia L Marcus; Tony Phengrasamy; Derek Blechinger; Dong Phuong Nguyen; Stephen Follansbee; C Bradley Hare Journal: Clin Infect Dis Date: 2015-09-01 Impact factor: 9.079
Authors: Matthew J Mimiaga; Sari L Reisner; Chris Grasso; Heidi M Crane; Steven A Safren; Mari M Kitahata; Joseph E Schumacher; W Christopher Mathews; Kenneth H Mayer Journal: Am J Public Health Date: 2013-06-13 Impact factor: 9.308
Authors: Whitney C Sewell; Victoria E Powell; Maya Ball-Burack; Kenneth H Mayer; Aileen Ochoa; Julia L Marcus; Douglas S Krakower Journal: J Acquir Immune Defic Syndr Date: 2021-09-01 Impact factor: 3.771
Authors: Carl G Streed; Jake R Morgan; Mam Jarra Gai; Marc R Larochelle; Michael K Paasche-Orlow; Jessica L Taylor Journal: JAMA Netw Open Date: 2022-07-01
Authors: Sarah K Calabrese; Douglas S Krakower; Tiara C Willie; Trace S Kershaw; Kenneth H Mayer Journal: Clin Infect Dis Date: 2019-08-16 Impact factor: 9.079
Authors: Maria Pyra; Laura K Rusie; Kristin Keglovitz Baker; Andie Baker; Jessica Ridgway; John Schneider Journal: Am J Public Health Date: 2020-01-16 Impact factor: 9.308
Authors: Chelsea L Shover; Steven Shoptaw; Marjan Javanbakht; Sung-Jae Lee; Robert K Bolan; Nicole J Cunningham; Matthew R Beymer; Michelle A DeVost; Pamina M Gorbach Journal: AIDS Behav Date: 2019-10
Authors: Afiba Manza-A Agovi; Ifedioranma Anikpo; Matthew J Cvitanovich; Esther O Fasanmi; Rohit P Ojha; Julia L Marcus Journal: J Acquir Immune Defic Syndr Date: 2021-11-01 Impact factor: 3.771
Authors: Caroline G Coleman; Jessica M Sales; Cam Escoffery; Kaitlin N Piper; Leah Powell; Anandi N Sheth Journal: J Gen Intern Med Date: 2021-01-14 Impact factor: 6.473